TrialPediatric blood & cancer2019
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
Michael S Isakoff et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this paperpooled ittrialcites it